Drugs – Page 61 – DES Daughter Network

Why Researchers MUST publish ALL Results of Clinical Trials

Make all medical research results public

A new campaign All trials registered, all results reported – supported by the Medical Research Council (publicly funded organisation in the UK dedicated to improving human health) – calls for the results of all clinical trials to be made public.
Sir Iain Chalmers, Coordinator of the James Lind Initiative, has strong words on researchers who hide trial results and ends his post by saying: “ If action is not taken urgently by research funders and regulators, information on what was done and what was found in trials could be lost forever, leading to bad treatment decisions, unnecessary repetition of trials, and missed opportunities for good medical practice. ”

Read Make all research results public, insight, 4 April 2013.
#AllTrials website and donation site.

Watch the Seattle Book Discussion about Bad Pharma

How Drug Companies Mislead Doctors and Harm Patients

Last February 18th, 2013, at Town Hall Seattle, Dr. Ben Goldacre talked about his book, Bad Pharma: How Drug Companies Mislead Doctors and Harm Patients, in which he discusses the influence of the pharmaceutical industry on the global healthcare system and argues that pharmaceutical companies hide negative studies and use questionable testing and intensive lobbying to get what they want, regardless of whether the drugs they produce are good for patients. Watch the video (1 hour, 26 minutes) .

More about Ben Goldacre

DES Videos in English – Diethylstilboestrol YT video channel.

Prenatal Dexamethasone for Congenital Adrenal Hyperplasia

Fetal Engineering Very Dangerous Experiment

Science Daily post Dangerous Experiment in Fetal Engineering analyses Prenatal Dexamethasone for Congenital Adrenal Hyperplasia published in the Journal of Bioethical Inquiry using extensive Freedom of Information Act findings to detail an extremely troubling off-label medical intervention employed in the U.S. on pregnant women to intentionally engineer the development of their fetuses for sex normalization purposes.

2012 Study Abstract

Following extensive examination of published and unpublished materials, we provide a history of the use of dexamethasone in pregnant women at risk of carrying a female fetus affected by congenital adrenal hyperplasia (CAH). This intervention has been aimed at preventing development of ambiguous genitalia, the urogenital sinus, tomboyism, and lesbianism. We map out ethical problems in this history, including: misleading promotion to physicians and CAH-affected families; de facto experimentation without the necessary protections of approved research; troubling parallels to the history of prenatal use of diethylstilbestrol (DES); and the use of medicine and public monies to attempt prevention of benign behavioral sex variations. Critical attention is directed at recent investigations by the U.S. Food and Drug Administration (FDA) and Office of Human Research Protections (OHRP); we argue that the weak and unsupported conclusions of these investigations indicate major gaps in the systems meant to protect subjects of high-risk medical research.

This is insane ! This shows NOTHING has been learned from the thalidomide and DES experiences.

Read Dangerous Experiment in Fetal Engineering.
Read Prenatal Dexamethasone for Congenital Adrenal Hyperplasia.
Read the Original Research and Download PDF.

Notice de Distilbène® DES, prescrit en France jusqu’à 1977…

…”utilement employé dans: menaces d’avortement”. ! ? ! ?

Le Distilbène DES, en savoir plus

Big Pharma and Doctors, or the Influence of the Pharmaceutical Industry

Why do so many doctors still think they are invincible to Big Pharma’s influence?

” The bottom line for any for-profit company is to sell their product, and since the pharmaceutical industry can’t sell drugs directly to patients, they convince doctors to prescribe them.
The more a doctor sees or hears the name of a drug, whether through drug reps, brochures or seeing the name on stationery, the more likely the drug is to be prescribed. ”

Read Doctors Are Under the Influence of Pharma Drugs by Ritika Goel, 04/02/2013.

Pay-to-delay Deals keep Consumer Prices artificially high to protect Drug Patent-Holders’ Profits

Pay-to-delay deals costly for the general public

” … When a company’s patent on a brand-name drug expires, other companies are free to make generic versions of the same drug… Often times, there are legal disputes between brand-name drug manufacturers and generic-drug companies. It’s increasingly common for this litigation to end with out-of-court settlements in which patentholders pay potential competitors to delay the introduction of generics.
That’s pay-to-delay… ”

Read PD Editorial: Pay-to-delay deals costly for consumers.

Read How ‘Pay for Delay’ Keeps Us Paying More for Prescription Drugs.